Anti-programmed cell death protein 1-based salvage therapy for relapsed/refractory Hodgkin lymphoma: a multicenter real-world analysis - PubMed
5 hours ago
- #PD-1 inhibitor
- #salvage therapy
- #Hodgkin lymphoma
- Anti-PD-1 salvage therapy shows promise for relapsed/refractory Hodgkin lymphoma (r/r cHL).
- PD-1 inhibitor-based regimens (monotherapy or combined with chemotherapy/BV) achieve high overall response (90.9%) and complete response (47.7%) rates.
- PD-1 + chemotherapy combinations (P-ICE/N-ICE/P-GVD) yield the best CR rates (61.3%).
- 1-year progression-free survival (PFS) was 83.9%, and overall survival (OS) was 95.6% in the study cohort.
- Patients with only one prior line of therapy had a 1-year PFS of 100%.
- Real-world data supports PD-1 inhibitor-based salvage followed by high-dose chemotherapy and autologous stem cell transplantation (HD-ASCT) for r/r cHL.